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Abstract Introduction Little is known about the preva-
lence of conditions potentially amenable to cellular therapy
among families storing umbilical cord blood in private cord
blood banks. Methods A cross-sectional study of families
with at least one child who stored umbilical cord blood in
the largest private cord blood bank in the United States was
performed. Respondent families completed a questionnaire
to determine whether children with stored cord blood or a
first-degree relative had one or more of 16 conditions
amenable primarily to allogeneic stem cell transplant
(‘‘transplant indications’’) or 16 conditions under investi-
gation for autologous stem cell infusion (‘‘regenerative
indications’’), regardless of whether they received a
transplant or infusion. Results 94,803 families responded,
representing 33.3 % of those surveyed. Of respondent
families, 16.01 % indicated at least one specified condi-
tion. 1.64 % reported at least one first-degree member with
a transplant indication potentially treatable with an
allogeneic stem cell transplant. The most common trans-
plant indications reported among first-degree family
members were Non-Hodgkin’s Lymphoma (0.33 %),
Hodgkin’s Lymphoma (0.30 %), and Acute Lymphoblastic
Leukemia (0.28 %). 4.23 % reported at least one child with
a regenerative indication potentially treatable with an
autologous stem cell infusion. The most common regen-
erative indications among children with stored umbilical
cord blood were Autism/Autism Spectrum Disorder/
Apraxia (1.93 %), Other Developmental Delay (1.36 %),
and Congenital Heart Defect (0.87 %). Discussion Among
families storing umbilical cord blood in private cord blood
banks, conditions for which stem cell transplant or infusion
may be indicated, or are under investigation, appear to be
prevalent, especially for regenerative medicine indications.
Keywords Hematopoietic stem cells  Stem cell
transplant  Regenerative medicine  Cord blood stem cell
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Significance
The identification of umbilical cord blood (UCB) as a
source of stem cells has made cord blood banking an
important topic. Yet, among families with stored UCB, the
prevalence of conditions either known to be treatable or
under investigation for treatment with UCB is largely
unknown. We believe this is the first study of disease
prevalence in a private cord blood bank. Among families
surveyed, 1.64 % reported at least one first-degree member
with an indication potentially treatable with an allogeneic
stem cell transplant, while 4.23 % reported at least one
child with an indication under investigation for treatment
with an autologous stem cell infusion.
Introduction
Umbilical cord blood (UCB) is a rich source of
hematopoietic stem cells. Since the first successful sibling
cord blood transplant for Fanconi anemia in 1988, UCB has
been used to treat a variety of life-threatening conditions,
including hematologic malignancies, hemoglobinopathies,
and metabolic and immune disorders (Gluckman et al.
2011). More recently, research has suggested that UCB has
the potential to play a role in regenerative medicine
applications where it may promote repair of organs and
tissues outside of its hematopoietic lineage (Harris et al.
2007; Willert et al. 2008). In these applications, it is
thought that UCB may repair damaged tissues either via
cell differentiation and replacement or, more likely,
through the release of anti-inflammatory and other factors
that stimulate endogenous repair mechanisms (Willert et al.
2008; Hau et al. 2008; Neuhoff et al. 2007). As a result,
new applications for UCB are now actively being investi-
gated in the laboratory and in clinical trials. Currently, ten
US- based clinical trials are being conducted in pediatric
populations to investigate the regenerative medicine
potential of UCB (Electronic Resource 1). A range of
conditions are being studied including cerebral palsy,
hearing loss, hypoplastic left heart syndrome, hypoxic-is-
chemic encephalopathy, pediatric stroke, type I diabetes,
and autism (‘‘US National Institutes,’’ 2015).
Traditionally, in transplant medicine, UCB from a
healthy, human leukocyte antigen (HLA)-matched donor
is used in an allogeneic transplant to repopulate the
recipient’s bone marrow after a pre-conditioning regimen.
In contrast, in the United States, the experimental use of
UCB for regenerative medicine indications is often
referred to as a stem cell ‘‘infusion’’ and almost always
autologous. Therefore, although autologous transplants
may be performed for traditional indications and allo-
geneic infusions may be performed for regenerative
indications, for the purpose of this study, the term
‘‘transplant indications’’ refers exclusively to medical
conditions for which UCB transplants are more likely to
be done in an allogeneic fashion whereas, the term ‘‘re-
generative indications’’ refers exclusively to medical
conditions for which UCB infusions are more be likely to
be done in an autologous fashion.
Until recently, UCB was considered medical waste
(Forraz and McGuckin 2011; Badowski and Harris 2012).
Soon after the first successful demonstration of UCB as a
stem cell source, cord blood banking was established in the
United States. As of 2013, it was conservatively estimated
that at least 1.36 million cord blood units were banked in
the United States (‘‘Parent’s Guide to Cord Blood,’’ 2014).
Families have the choice to either store cord blood in a
private cord blood bank or to donate it to the public cord
blood banking system. Private and public cord blood banks
are designed to serve different needs. For a fee, private
banks reserve the cord blood unit exclusively for use by the
donor and immediate family members, while UCB donated
to a public bank may be used by any patient in need,
though rarely the actual donor. Private cord blood banking
continues to grow. According to a 2009 estimate, private
cord blood banks now store approximately 60 % of the
more than half million UCB units processed each year
worldwide (‘‘World Stem Cell Summit,’’ 2009).
Despite growing participation, little information has
been collected on families who choose to privately bank
their children’s UCB. This study was carried out to better
characterize this population and to determine the preva-
lence of diseases and conditions potentially amenable to
UCB transplants or infusions among families at a large
private cord blood bank.
Methods
Study Population and Design
We conducted a cross-sectional survey using an online,
one-page Family Health Questionnaire (FHQ) of self-re-
ported disease prevalence among all eligible families with
at least one living child with stored UCB. These families
were identified using a contact database maintained by the
largest private cord blood bank in the United States. All
families that elected to collect and store UCB from January
1994 to May 2014 were initially included. Families were
ineligible to receive an FHQ if they did not have a valid
e-mail address on file in the company database, had a ‘‘do-
not-contact’’ request in place, had a deceased child with
stored UCB, or had a deceased primary parent contact.
Additionally, families with only adopted or surrogate births
were not included due to the FHQ’s focus on biological
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relatives. These exclusions accounted for approximately
17 % of the active storage population.
Survey Instrument
The FHQ was designed to determine whether a child with
stored UCB, or a first-degree relative of that child, cur-
rently had one or more listed diseases or conditions. This
survey captured self-reported information from the child’s
primary caregiver using check boxes for 16 transplant
indications and for 16 regenerative indications. The trans-
plant indications were selected based on documented effi-
cacy of UCB transplants for these indications, while the
regenerative indications were selected based on clinical
trials and other case series designed to explore the efficacy
of UCB for those indications. Information was collected
regardless of whether families had already received or
planned to receive a transplant or infusion. Instructions as
well as access to the FHQ were sent to eligible families via
e-mail. The questionnaire was sent in two main waves in
October 2013 and May 2014. After initial contact, non-
responding families were reminded via e-mail at least two
more times to complete the FHQ. These data were col-
lected as a preliminary activity for an IRB-approved, lon-
gitudinal study (E&I Review Board).
Statistical Analysis
Available demographic information was extracted from
cord blood bank enrollment forms and used to compare
responders versus non-responders. Potential non-response
bias based on respondent age, age of children with stored
cord blood, and number of stored cord blood units per
family was assessed and adjusted for using inverse prob-
ability weighting (IPW) (Seaman and White 2013).
To fully describe the prevalence of diseases among the
private cord blood bank population, three different mea-
sures were calculated based on respondent self-report.
First, an overall condition prevalence was calculated by
dividing the number of unique families that reported at
least one of the listed transplant or regenerative indications
by the total number of families responding to the survey.
Second, a transplant indication prevalence was calculated
as the proportion of families reporting at least one first-
degree member with a transplant indication potentially
treatable with an allogeneic cord blood transplant. Donor
children were excluded from this analysis since autologous
transplant would be less likely for these indications. Third,
a regenerative indication prevalence was calculated as the
proportion of families reporting at least one child with a
regenerative indication potentially treatable with an autol-
ogous cord blood infusion. Summary prevalences are
reported with 95 % confidence intervals. The data were




As of May 8, 2015, FHQs were sent to 284,982 eligible
families, representing 399,939 children with stored cord
blood. Of this group, 94,803 families (33.3 %), represent-
ing 134,635 children with stored cord blood units, com-
pleted FHQs. Geographically, more than 98 % of the
families surveyed (both respondents and non-respondents)
resided within the United States. Respondent primary
contacts (parents) had an average age of 39.9 years com-
pared to 40.1 for non-respondents. The average number of
cord blood units per family were nearly the same in both
the respondent and non-respondent groups; however,
because of the large sample size, small differences (e.g.
between 1.42 and 1.39 cord blood units per family) were
still statistically significant. Children with stored units were
between 0 and 23 years of age, with the children in the
respondent group being slightly younger than the children
in the non-respondent group (average age 6.0 vs. 6.4 years
old, respectively). To account for these differences,
adjusted prevalence rates were calculated using IPW
(Electronic Resource 2).
Family Health Questionnaire Conditions Indicated
Among families with stored UCB, the IPW-adjusted counts
showed that 1757 (1.86 %, 95 % CI 1.77–1.95 %) unique
families reported one or more of the 16 transplant indica-
tions, and 13,706 (14.50 %, 95 % CI 14.27–14.73 %)
unique families reported one or more of the 16 regenerative
indications. Thus, 16.36 % of families reported at least one
transplant indication and/or at least one regenerative indi-
cation. The majority of families (83.7 %) reported only one
condition and very few (0.35 %) reported both a transplant
and a regenerative condition. After accounting for the
small number of families that reported both a transplant
and a regenerative indication, 16.01 % (95 % CI
15.77–16.25 %) of unique respondent families indicated at
least one of the diseases specified on the FHQ.
Table 1 (Transplant indication prevalence) shows the
adjusted frequency of transplant indications among fami-
lies storing cord blood at a private bank. In addition, this
table provides a more conservative estimate of the fre-
quency of transplant indications by excluding families with
a transplant indication only in a child with stored cord
blood, since autologous infusions are less likely for trans-
plant indications in these children. For example, 323
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families providing FHQ responses indicated that a member
of the immediate family (father, mother, or children, pos-
sibly including the child with stored cord blood) had a
diagnosis of Non-Hodgkin’s Lymphoma. After excluding
families in which the child with the stored cord blood had
Non-Hodgkin’s Lymphoma, 314 families remained. With
this refinement, 1.64 % (95 % CI 1.55–1.72 %) of unique
respondent families had at least one first-degree relative,
excluding the donor child, with a transplant indication. The
most common transplant indications reported were Non-
Hodgkin’s Lymphoma (0.33 %), Hodgkin’s Lymphoma
(0.30 %), and Acute Lymphoblastic Leukemia (0.28 %).
Table 2 (Regenerative indication prevalence) shows the
adjusted frequency of regenerative indications among the
responding families. Since regenerative conditions are
more likely to be treated with autologous infusions, this
table provides a more conservative estimate of the fre-
quency of regenerative indications by only including
families with a regenerative indication in a child with
stored UCB. For example, 2885 families providing FHQ
responses indicated that a member of their immediate
family (father, mother, or children) had a diagnosis of
Autism/Autism Spectrum Disorder (ASD)/Apraxia. After
excluding families in which the member with Autism/
ASD/Apraxia was not the child with stored UCB, 1820
families remained. After this refinement, 4.23 % (95 % CI
4.10–4.36 %) of families had at least one child with stored
UCB and a regenerative indication. The most common
regenerative indications reported were Autism/ASD/
Apraxia (1.93 %), Other Developmental Delay (1.36 %),
and Congenital Heart Defect (0.87 %).
Although IPW-adjusted transplant, regenerative, and
specific indication proportions are reported, weighted and
unweighted figures did not differ materially (Electronic
Resources 3 and 4).
Discussion
While stem cell treatment is still a developing field, the
identification of UCB as a relatively abundant and ethically
uncontroversial source of stem cells has made cord blood
banking an important topic (Forraz and McGuckin 2011).
To our knowledge, this is the first cross-sectional study of
disease prevalence among families with stored UCB at a
private cord blood bank. From a list of 32 conditions, our
Table 1 Transplant indication prevalence (N = 94,539 respondent families)
Indicationa Families reporting transplant
indication (%)b
Families reporting transplant indication (not in child
donor) (%)b
Non-Hodgkin’s lymphoma 323 (0.34) 314 (0.33)
Hodgkin’s lymphoma 290 (0.31) 287 (0.30)
Acute lymphoblastic leukemia 328 (0.35) 263 (0.28)
Sarcoma 144 (0.15) 125 (0.13)
Acute myelogenous leukemia 113 (0.12) 106 (0.11)
Sickle cell disease 121 (0.13) 105 (0.11)
Beta thalassemia major 97 (0.10) 90 (0.10)
Chronic lymphocytic leukemia 88 (0.09) 85 (0.09)
Chronic myelogenous leukemia 82 (0.09) 82 (0.09)
Neuroblastoma 90 (0.10) 61 (0.06)
Multiple myeloma 60 (0.06) 58 (0.06)
Severe aplastic anemia 49 (0.05) 45 (0.05)
Myelodysplastic syndrome 20 (0.02) 19 (0.02)
Diamond–Blackfan anemia 10 (0.01) 9 (0.01)
Fanconi anemia 8 (0.01) 6 (0.01)
Hurler syndrome 0 (0.00) 0 (0.00)
Families reporting at least 1 transplant
indication
1823 (1.93) 1655 (1.75)
Unique families reporting at least 1 transplant
indication
1757 (1.86)c 1546 (1.64)c
a Families may report more than one indication. Ordered by percent of families reporting indication (not in child donor)
b Adjusted using inverse probability weighting based on respondent age, age of child, and number of cord blood units
c Percent represents total unique families reporting at least one transplant indication divided by the total families responding. This total is lower
than the sum of all specific transplant indications reported because families with more than 1 transplant indication were only counted once here
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survey of families who have banked UCB estimated that
16.01 % of unique families reported at least one disease or
condition currently treated with, or under investigation for
treatment with, UCB. Furthermore, after excluding autol-
ogous cord blood infusions for traditional transplant indi-
cations and allogeneic transplants for regenerative
indications, 1.64 % of unique families had at least one first-
degree member with a transplant condition potentially
amenable to allogeneic cord blood transplant while 4.23 %
of unique families had at least one child with a regenerative
condition potentially amenable to receiving an autologous
cord blood infusion.
Although this may be the first study to publish the
prevalence of various conditions in families with privately
stored UCB, other studies have looked at the likelihood of
utilization of banked UCB. For example, in 1997, Johnson
estimated the probability of clinical need for UCB by
multiplying the probability of developing a disease (based
on prevalence in the general population), by the probability
of need for transplantation (vs. other first-line therapies)
(Johnson 1997; Ballen et al. 2008). As part of his analysis,
Johnson estimated that 608 (0.30 %) of 200,000 babies
born each year face the risk of developing cancer or
another life threatening hematopoietic, immunodeficiency,
or genetic disease before adulthood. However, Johnson
went on to suggest that fewer than half of these children
(216, or 0.11 %) could actually benefit from an autologous
or allogeneic stem cell transplantation of UCB. Another
estimate of the likelihood of stem cell transplant was per-
formed more recently (Nietfeld et al. 2008). Nietfeld et al.
estimated the lifetime probability of hematopoietic stem
cell transplantation in the United States under four distinct
scenarios using data from the Center for International
Blood and Marrow Transplant Research, the United States
Table 2 Regenerative indication prevalence (N = 94,539 families)
Indicationa Families reporting regenerative
indication (%)b
Families reporting regenerative indication (only in
child donor) (%)b
Autism/ASD/apraxia 2885 (3.05) 1820 (1.93)
Other developmental delay 2119 (2.24) 1282 (1.36)
Congenital heart defectc 230 (1.86) 107 (0.87)
Childhood hearing loss 1097 (1.16) 378 (0.40)
Diabetes, type I 2374 (2.51) 247 (0.26)
Cerebral palsy/PVL/hypotonia 748 (0.79) 234 (0.25)
Inflammatory bowel disease 2218 (2.35) 128 (0.14)
Hydrocephalus 278 (0.29) 121 (0.13)
In-utero brain injury/stroke 233 (0.25) 98 (0.10)
Hypoxic-ischemic brain injury 270 (0.29) 77 (0.08)
Traumatic brain injury 344 (0.36) 54 (0.06)
Infant lung disease (e.g. bronchopulmonary
dysplasia)
100 (0.11) 49 (0.05)
Spinal cord injury 348 (0.37) 33 (0.03)
Muscular dystrophy 156 (0.17) 33 (0.03)
Diabetes, type II 2592 (2.74) 12 (0.01)
Systemic lupus 431 (0.46) 4 (0.00)
Families reporting at least 1 regenerative
indication
16,423 (17.37)d 4677 (4.95)d
Unique families reporting at least 1
regenerative indication
13,706 (14.50)e 4000 (4.23)e
ASD autism spectrum disorder, PVL periventricular leukomalacia
a Families may report more than one indication. Ordered by percent of families reporting indication (only in child donor)
b Adjusted using inverse probability weighting based on respondent age, age of child, and number of cord blood units
c Congenital heart defect appeared only on a subset of the surveys of which 12,366 were returned. Therefore, we calculated the prevalence based
on this lower denominator
d The sum of the percentages for all specific indications is more than the total number of regenerative indications divided by the sampled
population because the prevalence for congenital heart defect was calculated on a subset of families
e Percent represents unique families reporting at least one regenerative indication divided by total unique families responding. The total is lower
than the sum of regenerative indications (families with more than 1 regenerative indication were counted once)
212 Matern Child Health J (2017) 21:208–214
123
Surveillance, Epidemiology and End Results Program, and
the United States Census Bureau. It was estimated that the
cumulative lifetime probability of undergoing a
hematopoietic stem cell transplant ranged from 0.23 to
0.98 %.
This study’s prevalence estimates do not measure the
need for transplant; rather they measure the prevalence of
conditions that might be amenable to treatment with
transplant or infusion in a subset of those individuals. In
fact, there are many reasons why a patient or family
member with stored UCB might not receive a transplant or
infusion despite being diagnosed with a condition that is
potentially treatable with stem cells. For example, many of
the conditions amenable to UCB transplant are malignan-
cies, like lymphoma, with established treatments such as
radiation or chemotherapy that are often used successfully
prior to stem cell transplant (Isidori et al. 2015). For allo-
geneic transplants, there may not be an appropriate HLA
match since, for example, only 1 in 4 siblings of the same
biological parents are a haplo-identical HLA match (Butler
and Menitove 2011). Furthermore, some UCB units may
contain insufficient cell dose to be successfully used for
transplant, particularly in older children and adults (Page
et al. 2011). Other barriers to UCB infusion or transplant
may exist, including educational, cultural, and socioeco-
nomic factors. Longitudinal studies of this population may
help to better characterize and understand these barriers.
There are other substantive differences between the
prevalence estimates in this study and the likelihood of
transplant estimates from previous reports. Of note, neither
Johnson nor Nietfield accounted for the allogeneic trans-
plantation of UCB units to family members other than the
child with stored cells. Furthermore, neither study incor-
porated the potential use of UCB units in patients with
regenerative conditions.
This study has several limitations. The use of self-report
without clinical confirmation may have introduced mis-
classification of individuals and families. Also, our
response rate was 33.3 %, raising the question of non-re-
sponse bias. To help address this concern, we adjusted our
results using IPW. Furthermore, since study families paid
to store cord blood privately, they likely represent a group
with higher average socioeconomic status than the general
population, which could reduce the generalizability of this
study’s finding to populations beyond private cord blood
banks. However, since the goal of this study was to char-
acterize the population of families storing cells in private
cord blood banks, generalizability beyond this group was
not a key objective.
Millions of units of UCB are stored in private cord blood
banks. Before this study, the medical community had little
understanding of the conditions faced by the families who
choose to store their children’s UCB. This prevalence data,
combined with the results of ongoing clinical trials to
document the clinical impact of UCB for new indications,
should lead to a better understanding of the true potential of
this unique resource.
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